How is IPC Strengthening Pharmacovigilance and Materiovigilance in Nagaland?
Click to start listening
Synopsis
The Indian Pharmacopoeia Commission has signed three pivotal MoUs in Nagaland aimed at enhancing the monitoring of drug safety and adverse effects, marking a significant step in patient safety within the region's healthcare framework.
Key Takeaways
- IPC signed three MoUs for improved drug safety.
- Partnerships include Nagaland Medical Council and NSDCA.
- Aims to promote adverse event reporting.
- Enhances the safe use of medicines through the National Formulary of India.
- First MoU of its kind in the North Eastern region.
New Delhi, Nov 28 (NationPress) The Indian Pharmacopoeia Commission (IPC), based in Ghaziabad, has formalized three Memoranda of Understanding (MoU) with the Nagaland Medical Council, the Nagaland State Drugs Control Administration (NSDCA), the Department of Health & Family Welfare of Nagaland, and the State Pharmacy Council of the Government of Nagaland, as announced by the Ministry of Health on Friday.
The agreements were finalized during a one-day training session on pharmacovigilance and materiovigilance facilitated by the IPC in partnership with the NSDCA.
“This collaboration aims to enhance pharmacovigilance and materiovigilance, encourage adverse event reporting, build the capacity of stakeholders, broaden the reach of adverse drug reaction (ADR) monitoring centers and Medical Device Adverse Event Monitoring Centres (MDMCs), and promote the safe use of medicines through the National Formulary of India across healthcare facilities in Nagaland,” the Ministry stated.
Significantly, the MoU with the Nagaland Drugs Control Administration marks IPC's second MoU, following that with UPFDA, and is the first of its kind in the North Eastern region.
The MoU with the Nagaland Medical Council is the first of its kind with any State Medical Council in India, aimed at fostering the Pharmacovigilance Programme of India and the Materiovigilance Programme of India, focusing on enhancing patient safety at primary health centers nationwide.
The MoU with the State Pharmacy Council is the fourth in the country aimed at promoting the safe and rational use of medicines while boosting pharmacovigilance and materiovigilance initiatives.
Through these agreements, IPC is dedicated to collaborating with the NSDCA, Nagaland State Pharmacy Council, and Nagaland Medical Council to fortify pharmacovigilance and materiovigilance efforts. This includes promoting adverse event reporting related to drugs and medical devices and utilizing the National Formulary of India (NFI) as a standard reference in healthcare facilities across Nagaland, thereby supporting rational dispensing and safe medication practices, according to the Ministry.
Moreover, the MoUs are designed to enhance capacity building among all stakeholders, including healthcare professionals (physicians, pharmacists, nurses, etc.), scientific personnel responsible for quality control of medical products, and the safe use of medicines through the enforced use of the National Formulary of India.
“IPC is devoted to offering extensive technical guidance and expert support for these initiatives, while NSDCA and Nagaland State Pharmacy Council will coordinate with medical colleges, hospitals, pharmacists, drug inspectors, industry stakeholders, and other healthcare professionals from both public and private sectors to ensure successful execution of the agreed-upon activities,” the Ministry added.
Point of View
It is critical to acknowledge IPC's proactive approach in collaborating with Nagaland's healthcare bodies to enhance patient safety. This initiative is a significant stride toward ensuring that healthcare practices prioritize the well-being of individuals, particularly in underserved regions. NationPress stands firmly in support of such initiatives that aim to uplift healthcare standards across the country.
NationPress
28/11/2025
Frequently Asked Questions
What is the purpose of the MoUs signed by IPC?
The MoUs aim to strengthen pharmacovigilance and materiovigilance, promote adverse event reporting, and enhance the safe use of medicines across healthcare facilities in Nagaland.
Who are the partners involved in the MoUs?
The partners are the Nagaland Medical Council, Nagaland State Drugs Control Administration (NSDCA), and the State Pharmacy Council of the Government of Nagaland.
How will these MoUs impact healthcare in Nagaland?
These agreements will lead to improved monitoring of adverse drug reactions and medical device events, thereby enhancing patient safety and healthcare standards.
Is this the first MoU of IPC in the North Eastern region?
Yes, this is IPC's first MoU in the North Eastern region, marking a significant development for healthcare collaboration in that area.
What is the National Formulary of India?
The National Formulary of India is a standard reference document that supports safe and rational dispensing of medicines across healthcare facilities.
